Forgot your password?
Document Actions
Testing Methods for Improving Emotional Salience of Risk Information: Results from a Decision Aid about Tamoxifen and Raloxifene
We have previously shown that when patients learn about the risks and benefits of tamoxifen, women at high risk of breast cancer are overwhelmingly not interested. In this study, we tested 5 additional factors for communicating the risks/benefits of tamoxifen (and now a second prevention drug, raloxifene). These factors also included manipulations that could affect the emotional salience of the risk/benefit message. In this talk, I will describe the factors studied and their impact on knowledge, risk perception, behavioral intentions, and actual behavior.
2009-05-28 00:00
2009-05-28 12:00
2009-05-28 13:30
Angela Fagerlin, PhD
Angie Fagerlin is an associate professor in the Center for Behavioral and Decision Sciences in Medicine at the Ann Arbor Veterans Affairs Health Services Research & Development Service and the University of Michigan (Internal Medicine). Her research interests includes testing methods for improving the communication of risks and benefits of treatments, particularly for patients who have poor numeracy skills. She is also interested in the factors that influence people's decisions about medical care. She has written extensively about the use of living wills in end-of-life decision making.
6D15 NIB (new room for 2009)
http://wocket.chcr.med.umich.edu/chcr/seminars/2009-05-28-fagerlin.htm
28-May-2009-fagerlin.pdf
(
Upcoming Seminar - December 17th: Laurel Northouse
